What topics does this cannabis study cover?

This study covers research on: THC, Inflammation.

Where was this research published?

Published in Journal of cannabis research on June 3, 2026.

THC-cannabis shows limited effectiveness for inflammatory bowel disease

Q: What did this Review find?

This systematic review examined whether **THC-containing cannabis products** could effectively treat inflammatory bowel disease (IBD), a condition where the digestive tract becomes chronically inflamed. Researchers analyzed four randomized controlled trials and four observational studies involving

Effectiveness of THC-containing cannabis for inflammatory bowel disease: a systematic review.

Journal of cannabis research • June 3, 2026 • Review • Moderately Relevant

🤖

AI Summary

This systematic review examined whether THC-containing cannabis products could effectively treat inflammatory bowel disease (IBD), a condition where the digestive tract becomes chronically inflamed. Researchers analyzed four randomized controlled trials and four observational studies involving patients who used cannabis for IBD symptoms. The review followed rigorous scientific standards (PRISMA and Cochrane guidelines) to ensure credibility, though all studies examined had high risk of bias, limiting how much we can trust the results.

The findings were disappointingly inconclusive. While a small trial (n=56) reported improvements in bloating and appetite, most other outcomes—including disease remission, pain, nausea, weight, and bowel movement frequency—showed no meaningful differences between cannabis and control groups. Results for clinical disease activity scores, quality of life, and general well-being were mixed, with evidence quality ranging from low to moderate. Only weight showed high-quality evidence, but even then, there was no effect reported. The researchers emphasized that safety information was extremely limited across the trials.

The bottom line: despite widespread use of cannabis among IBD patients, current scientific evidence does not demonstrate that THC-containing products are effective for treating IBD. The researchers called for higher-quality, well-designed studies to better understand whether cannabis has any genuine therapeutic role. This review is particularly important because many IBD patients self-medicate with cannabis, making rigorous evidence crucial for informed decision-making.

📄 Original Abstract

Patients with inflammatory bowel disease (IBD) increasingly use cannabis. Studies investigating the effectiveness and safety of cannabis as a therapeutic option for IBD have reported conflicting findings, and recent reviews have not incorporated evidence from real-world studies. This systematic review assessed controlled non-interventional studies and interventional trials evaluating the effectiveness of delta-9-tetrahydrocannabinol (THC)-containing cannabis products in patients with IBD. The systematic review procedures-including search strategy across four databases, literature screening, data extraction, qualitative result synthesis, and risk of bias assessment-followed the Cochrane Handbook and adhered to PRISMA-compliant reporting. We used the GRADE approach to rate evidence quality for each outcome. peer-reviewed research on effectiveness or safety of cannabis as treatment modality, control group must be present, quantitative measure of effect/safety on IBD. published before 2000, non-English, non-human research, non-cannabis/THC exposures, < 0.3% THC exposure, topical formulations. Four randomized clinical trials (RCTs), and four non-interventional studies met all inclusion criteria. Non-interventional studies exhibited serious or critical risk of bias, leading to their exclusion from evidence ratings. The four RCTs demonstrated high risk of bias, although their evidence quality ratings varied. RCTs assessed adverse events; however, limited safety information was provided. Improvements in one trial were reported for bloating (n = 56) and appetite (n = 56), both rated as low evidence quality. Results for clinical disease activity scores (4 trials, n = 180), daily function, general well-being, general effect on health (1 trial, n = 56), bowel movement frequency (3 trials, n = 148), generic quality of life (3 trials, n = 122) and pain (2 trials, n = 88) were mixed. The outcomes of remission (3 trials, n = 150), weight (1 trial, n = 56), IBDQ (1 trial, n = 60), endoscopic scores (2 trials, n = 88), and nausea (1 trial, n = 56), consistently failed to differ meaningfully between intervention and control. The evidence quality rating for these null or inconclusive results varied from low to medium, with the exception of weight, rated as high, though no effect was reported. Current evidence is inconclusive as to whether THC-containing cannabis products might have a positive effect in IBD, given heterogenous findings and mostly low-to-moderate evidence quality. Higher quality cannabis research is needed given widespread utilization. PROSPERO: CRD42023411910.

Paper Type

📚 Review

Publication

Journal: Journal of cannabis research
Published: June 3, 2026
PMID: 42231518
DOI: 10.1186/s42238-026-00456-2

Authors (13)

Sebastian Jugl Department of Pharmaceutical Outcomes and Policy, University of Florida, 6018 Malachowsky Hall, Gainesville, FL, 32611, USA.
Silvia Perez-Vilar Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
Steven Galati Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
Sukhminder K Sandhu Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
Hung-Kai Chen Department of Pharmaceutical Outcomes and Policy, University of Florida, 6018 Malachowsky Hall, Gainesville, FL, 32611, USA.
+8 more authors